NORGENOTECH AS

Their core work

NORGENOTECH AS is a small Norwegian private company working at the intersection of molecular biology and nanotechnology risk science. Their research contributions span chromatin biology and the cellular DNA damage response — the mechanisms cells use to detect and repair DNA breaks — as well as computational approaches for assessing the safety of engineered nanomaterials. They participate as specialist partners in European training and staff-exchange networks, contributing domain expertise rather than laboratory infrastructure. Their work sits in a niche where biological knowledge of how cells respond to genetic insults informs how we model and predict the hazards of nano-scale materials.

What they specialise in

How they've shifted over time

NORGENOTECH entered H2020 through fundamental cell biology — chromatin structure, histones, and how cells detect and repair DNA double-strand breaks. By 2021, their focus had shifted toward applied nanotechnology regulation: nanoinformatics, nanoform classification, and computational safe-by-design frameworks. The shift is consistent with a research-oriented SME following the growing EU regulatory demand for predictive nanosafety tools, where knowledge of DNA damage mechanisms (a core biological endpoint for nanomaterial toxicity) provides direct scientific grounding.

NORGENOTECH appears to be moving from fundamental molecular biology toward computational nanosafety science — a direction strongly aligned with EU regulatory priorities around nanomaterial risk assessment and REACH compliance.

How they like to work

NORGENOTECH has exclusively participated as a consortium member, never as a coordinator, across both projects. They operate within large MSCA networks — training networks and staff-exchange programmes — suggesting they contribute specialist knowledge to multi-partner consortia rather than driving project strategy. With 38 distinct partners across 24 countries reached through only two projects, their network breadth is the result of the large consortium structures typical of MSCA-ITN and MSCA-RISE schemes, not a sign of independent network-building.

NORGENOTECH has connected with 38 unique partners across 24 countries through just two projects, reflecting the wide geographic spread of MSCA networks rather than independent outreach. No repeated partner clusters are visible from the available data.

What sets them apart

NORGENOTECH occupies an unusual position as a private SME operating inside MSCA training and researcher-exchange networks — a space dominated by universities and public research institutes. Their combination of molecular biology expertise (DNA damage, chromatin) and emerging nanoinformatics competence positions them at a biologically grounded entry point into the nanosafety field, which is increasingly relevant for REACH nanoform regulation. For a consortium builder, they offer private-sector participation in fundamental-to-applied research chains without the overhead of a large institution.

Highlights from their portfolio

• aDDRess
  Their largest project by far at EUR 292,342 — an MSCA Innovative Training Network on chromatin dynamics and DNA damage response, signalling genuine research depth in a highly specialized area of cell biology.
• CompSafeNano
  Represents a strategic pivot toward nanoinformatics and computational nanosafety, a field under active EU regulatory development, with participation running through 2026.